David Edward Johnson
David Edward Johnson's purchase track record
How the stock did after each of David Edward Johnson's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/25/2025 | EXEL | $1.19M | +4.7% | +15.9% | +11.1% |
| 5/28/2024 | EXEL | $8.73M | +26.5% | +79.2% | +13.5% |
| 2/21/2024 | EXEL | $3.93M | +1.4% | +27.1% | +12.8% |
| 11/27/2023 | EXEL | $2.60M | +1.6% | -5.9% | +16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Transaction History
| LQDA | ▲ Buy | Grant | 5,882 | $0 | 6/16/2026 | View on chart |
| EXEL | ▲ Buy | Open Market | 27,532 | $1.2M | 11/25/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 18,396 | $0 | 6/17/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 20,359 | $0 | 6/20/2024 | View on chart |
| EXEL | ▲ Buy | Open Market | 225,000 | $4.7M | 5/30/2024 | View on chart |
| EXEL | ▲ Buy | Open Market | 200,000 | $4.1M | 5/28/2024 | View on chart |
| EXEL | ▲ Buy | Open Market | 190,000 | $3.9M | 2/21/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 120,409 | $2.6M | 11/27/2023 | View on chart |
| EXEL | ▲ Buy | Open Market | 120,409 | $2.6M | 11/27/2023 | View on chart |
| EXEL | ▲ Buy | Grant | 18,176 | $0 | 5/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.